Axovant Sciences Ltd Company Profile (NYSE:AXON)

About Axovant Sciences Ltd (NYSE:AXON)

Axovant Sciences Ltd logoAxovant Sciences Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on acquiring, developing and commercializing therapeutics for the treatment of dementia, including Alzheimer's disease and Lewy body dementia. The Company intends to develop a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders. The Company is focused to develop its lead product candidate, intepirdine, a selective 5-hydroxytryptamine 6 receptor antagonist, for the treatment of Alzheimer's disease and dementia with Lewy bodies (DLB). The Company also focuses on developing nelotanserin, a selective 5-hydroxytryptamine 2A receptor inverse agonist, for the treatment of rapid eye movement (REM) behavior disorder (RBD) in DLB patients, and visual hallucinations in patients with Lewy body dementia. The Company's pipeline also includes RVT-103 and RVT-104.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Symbol: NYSE:AXON
  • CUSIP: N/A
  • Web: www.axovant.com
Capitalization:
  • Market Cap: $2.15 billion
  • Outstanding Shares: 99,161,000
Average Prices:
  • 50 Day Moving Avg: $22.24
  • 200 Day Moving Avg: $15.51
  • 52 Week Range: $11.01 - $25.18
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -10.01
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $1.68 per share
  • Price / Book: 12.93
Profitability:
  • EBIDTA: ($157,950,000.00)
  • Return on Equity: -69.27%
  • Return on Assets: -64.31%
Debt:
  • Current Ratio: 8.19%
  • Quick Ratio: 8.19%
Misc:
  • Average Volume: 705,469 shs.
  • Beta: 0.45
  • Short Ratio: 11.4
 

Frequently Asked Questions for Axovant Sciences Ltd (NYSE:AXON)

What is Axovant Sciences Ltd's stock symbol?

Axovant Sciences Ltd trades on the New York Stock Exchange (NYSE) under the ticker symbol "AXON."

How were Axovant Sciences Ltd's earnings last quarter?

Axovant Sciences Ltd (NYSE:AXON) announced its quarterly earnings results on Tuesday, February, 14th. The company reported ($0.48) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.45) by $0.03. View Axovant Sciences Ltd's Earnings History.

When will Axovant Sciences Ltd make its next earnings announcement?

Axovant Sciences Ltd is scheduled to release their next quarterly earnings announcement on Monday, June, 5th 2017. View Earnings Estimates for Axovant Sciences Ltd.

Where is Axovant Sciences Ltd's stock going? Where will Axovant Sciences Ltd's stock price be in 2017?

11 brokers have issued 12 month price objectives for Axovant Sciences Ltd's shares. Their forecasts range from $7.50 to $36.00. On average, they expect Axovant Sciences Ltd's stock price to reach $28.14 in the next twelve months. View Analyst Ratings for Axovant Sciences Ltd.

What are analysts saying about Axovant Sciences Ltd stock?

Here are some recent quotes from research analysts about Axovant Sciences Ltd stock:

  • 1. According to Zacks Investment Research, "Axovant Sciences Ltd. is a biopharmaceutical company which focuses on the acquisition, development and commercialization of therapeutics for the treatment of neurodegenerative disorders. Its product candidate includes RVT-101 which is in different clinical trial for the treatment of Alzheimer's disease and other forms of dementia. Axovant Sciences Ltd. is based in Hamilton, Bermuda. " (3/9/2017)
  • 2. Piper Jaffray Companies analysts commented, "We see these results as mixed but positive for the company's first foray into this under-studied disease. First off, nelo' did appear safe/well tolerated, which was a non-zero risk in this population. In addition, the study suggested some benefit on ADL and motor function ' not exactly what we were expecting, but if replicated could address a key unmet need in DLB especially. We didn't yet see improvement on visual hallucinations but longer dosing in more patients may be helpful here. We'll await full results around mid'17, and remain optimistic these results and/or the DLB-RBD study will inform a Phase III program for nelo' in at least one LBD symptom complex. For now, nelo' is upside to our valuation and we remain focused on the pivotal programs for RVT-101 in AD and DLB." (2/13/2017)

Who are some of Axovant Sciences Ltd's key competitors?

When did Axovant Sciences Ltd IPO?

(AXON) raised $251 million in an initial public offering on Thursday, June 11th 2015. The company issued 17,900,000 shares at a price of $13.00-$15.00 per share. Jefferies, Evercore ISI and RBC Capital Markets served as the underwriters for the IPO and JMP Securities and Baird were co-managers.

Who owns Axovant Sciences Ltd stock?

Axovant Sciences Ltd's stock is owned by many different of retail and institutional investors. Top institutional investors include Janus Capital Management LLC (4.54%), Primecap Management Co. CA (0.00%), FMR LLC (0.00%), JPMorgan Chase & Co. (0.00%), VHCP Management II LLC (0.00%) and Blackstone Group L.P. (0.36%). Company insiders that own Axovant Sciences Ltd stock include David Hung, Mark Altmeyer and W Anthony Vernon. View Institutional Ownership Trends for Axovant Sciences Ltd.

Who sold Axovant Sciences Ltd stock? Who is selling Axovant Sciences Ltd stock?

Axovant Sciences Ltd's stock was sold by a variety of institutional investors in the last quarter, including Janus Capital Management LLC, Morgan Stanley, Deltec Asset Management LLC, Credit Suisse AG, TIAA CREF Investment Management LLC, Alliancebernstein L.P. and Bourgeon Capital Management LLC. View Insider Buying and Selling for Axovant Sciences Ltd.

Who bought Axovant Sciences Ltd stock? Who is buying Axovant Sciences Ltd stock?

Axovant Sciences Ltd's stock was acquired by a variety of institutional investors in the last quarter, including Primecap Management Co. CA, Point72 Asset Management L.P., C WorldWide Group Holding A S, Candriam Luxembourg S.C.A., Nationwide Fund Advisors, JPMorgan Chase & Co., Oppenheimer & Co. Inc. and Woodstock Corp. Company insiders that have bought Axovant Sciences Ltd stock in the last two years include David Hung, Mark Altmeyer and W Anthony Vernon. View Insider Buying and Selling for Axovant Sciences Ltd.

How do I buy Axovant Sciences Ltd stock?

Shares of Axovant Sciences Ltd can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Axovant Sciences Ltd stock cost?

One share of Axovant Sciences Ltd stock can currently be purchased for approximately $21.73.

Analyst Ratings

Consensus Ratings for Axovant Sciences Ltd (NYSE:AXON) (?)
Ratings Breakdown: 1 Sell Rating, 2 Hold Ratings, 8 Buy Ratings
Consensus Rating:Buy (Score: 2.64)
Consensus Price Target: $28.14 (29.48% upside)

Analysts' Ratings History for Axovant Sciences Ltd (NYSE:AXON)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
4/18/2017CIBCBoost Price TargetNeutral$30.00 -> $33.00LowView Rating Details
4/18/2017Jefferies Group LLCReiterated RatingBuy$31.00LowView Rating Details
4/17/2017Oppenheimer Holdings Inc.Boost Price TargetNeutral$30.00 -> $33.00LowView Rating Details
4/12/2017Piper Jaffray CompaniesReiterated RatingOverweight$32.00LowView Rating Details
2/14/2017HC WainwrightSet Price TargetBuy$35.00N/AView Rating Details
2/14/2017Cowen and CompanyInitiated CoverageOutperformN/AView Rating Details
12/20/2016Robert W. BairdReiterated RatingPositive$29.00N/AView Rating Details
12/20/2016LaidlawInitiated CoverageSell$7.50N/AView Rating Details
11/8/2016JMP SecuritiesReiterated RatingBuyN/AView Rating Details
9/23/2016Evercore ISIReiterated RatingBuy$29.00N/AView Rating Details
6/30/2016Leerink SwannReiterated RatingBuyN/AView Rating Details
2/3/2016Chardan CapitalReiterated RatingSell$8.00N/AView Rating Details
7/6/2015Evercore Partners Inc.Initiated CoverageBuy$29.00N/AView Rating Details
7/6/2015Royal Bank of CanadaInitiated CoverageOutperform$40.00N/AView Rating Details
(Data available from 5/28/2015 forward)

Earnings

Earnings History for Axovant Sciences Ltd (NYSE:AXON)
Earnings by Quarter for Axovant Sciences Ltd (NYSE:AXON)
Earnings History by Quarter for Axovant Sciences Ltd (NYSE:AXON)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
6/5/2017        
2/14/2017Q3($0.45)($0.48)ViewN/AView Earnings Details
8/15/2016Q1($0.36)($0.38)ViewN/AView Earnings Details
6/6/2016Q4 2016($0.30)($0.30)ViewN/AView Earnings Details
2/9/2016Q315($0.15)($0.64)ViewN/AView Earnings Details
11/2/2015Q215($0.24)($0.12)ViewN/AView Earnings Details
8/11/2015Q115($0.10)($0.35)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Axovant Sciences Ltd (NYSE:AXON)
Current Year EPS Consensus Estimate: $-1.81 EPS
Next Year EPS Consensus Estimate: $-2.17 EPS

Dividends

Dividend History for Axovant Sciences Ltd (NYSE:AXON)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Axovant Sciences Ltd (NYSE:AXON)
Insider Ownership Percentage: 3.10%
Insider Trades by Quarter for Axovant Sciences Ltd (NYSE:AXON)
Institutional Ownership by Quarter for Axovant Sciences Ltd (NYSE:AXON)
Insider Trades by Quarter for Axovant Sciences Ltd (NYSE:AXON)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
4/17/2017David HungInsiderBuy539,375$18.54$10,000,012.50View SEC Filing  
4/17/2017W Anthony VernonDirectorBuy53,937$18.54$999,991.98View SEC Filing  
3/10/2016Mark AltmeyerInsiderBuy2,300$11.14$25,622.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Axovant Sciences Ltd (NYSE:AXON)
Latest Headlines for Axovant Sciences Ltd (NYSE:AXON)
Source:
DateHeadline
nasdaq.com logoCommit To Purchase Axovant Sciences At $12.50, Earn 103.3% Annualized Using Options - Nasdaq
www.nasdaq.com - May 26 at 4:05 PM
americanbankingnews.com logoAxovant Sciences Ltd (AXON) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - May 19 at 9:24 AM
americanbankingnews.com logo-$0.51 EPS Expected for Axovant Sciences Ltd (AXON) This Quarter
www.americanbankingnews.com - April 28 at 11:13 AM
seekingalpha.com logoInsider Transactions Weekly Newsletter
seekingalpha.com - April 26 at 4:05 PM
americanbankingnews.com logoAxovant Sciences Ltd (AXON) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - April 24 at 11:36 AM
rttnews.com logoCompany Spotlight: Axovant Sciences
www.rttnews.com - April 22 at 10:21 AM
nasdaq.com logoCompany Spotlight: Axovant Sciences - Nasdaq
www.nasdaq.com - April 21 at 3:50 PM
americanbankingnews.com logoAxovant Sciences Ltd (AXON) Insider David Hung Buys 539,375 Shares
www.americanbankingnews.com - April 19 at 10:45 PM
americanbankingnews.com logoInsider Buying: Axovant Sciences Ltd (AXON) Director Acquires 53,937 Shares of Stock
www.americanbankingnews.com - April 19 at 10:45 PM
finance.yahoo.com logoAxovant: A New CEO Doesn't Change Anything
finance.yahoo.com - April 19 at 10:22 AM
americanbankingnews.com logoAxovant Sciences Ltd (AXON) Price Target Raised to $33.00
www.americanbankingnews.com - April 18 at 5:36 PM
americanbankingnews.com logoJefferies Group LLC Reiterates "Buy" Rating for Axovant Sciences Ltd (AXON)
www.americanbankingnews.com - April 18 at 11:16 AM
finance.yahoo.com logoAxovant Sciences Ltd. Announces Closing of Public Offering and Exercise in Full of the Underwriters' Option to Purchase Additional Common Shares
finance.yahoo.com - April 18 at 11:16 AM
americanbankingnews.com logoOppenheimer Holdings Inc. Raises Axovant Sciences Ltd (AXON) Price Target to $33.00
www.americanbankingnews.com - April 17 at 4:16 PM
americanbankingnews.com logoAxovant Sciences Ltd (AXON) Stock Rating Reaffirmed by Oppenheimer Holdings Inc.
www.americanbankingnews.com - April 15 at 9:12 AM
americanbankingnews.com logoAxovant Sciences' (AXON) "Overweight" Rating Reiterated at Piper Jaffray Companies
www.americanbankingnews.com - April 14 at 11:00 AM
finance.yahoo.com logoImplied Volatility Surging for Axovant Sciences (AXON) Stock Options - Yahoo Finance
finance.yahoo.com - April 13 at 3:56 PM
finance.yahoo.com logoShark Bites: You Don't Want to Play the Gambler Today
finance.yahoo.com - April 13 at 3:56 PM
finance.yahoo.com logoAxovant Sciences (AXON) Shows Strength: Stock Jumps 9.2%
finance.yahoo.com - April 12 at 11:38 AM
finanznachrichten.de logoGainers & Losers Of Apr.10: CYTX, AXON, GERN, OMED, TXMD...
www.finanznachrichten.de - April 11 at 8:49 PM
streetinsider.com logoAxovant Sciences (AXON) Commences $100M Common Stock Offering
www.streetinsider.com - April 11 at 8:49 PM
rttnews.com logoAxovant Sciences Ltd. (AXON) Broke Out To A New High After New CEO Named
www.rttnews.com - April 11 at 8:49 PM
finance.yahoo.com logoAxovant Sciences Ltd. Announces $100 Million Public Offering of Common Shares
finance.yahoo.com - April 11 at 8:49 PM
finance.yahoo.com logoAxovant CEO David Hung Promises To Invest $10 Million As Company Moves To Raise $100 Million
finance.yahoo.com - April 11 at 8:49 PM
finance.yahoo.com logoAxovant Sciences Ltd. Announces Pricing of $125M Public Offering of Common Shares
finance.yahoo.com - April 11 at 8:49 PM
finance.yahoo.com logoNew Captain, Same Ship for Axovant
finance.yahoo.com - April 11 at 8:49 PM
nasdaq.com logoBUZZ-U.S. STOCKS ON THE MOVE-UAL, AmTrust, RetailMeNot, Apple, Cytori, Axovant - Nasdaq
www.nasdaq.com - April 11 at 3:48 PM
streetinsider.com logoAxovant Sciences (AXON) Commences $100M Common Stock Offering - StreetInsider.com
www.streetinsider.com - April 11 at 3:48 PM
nasdaq.com logoBUZZ-U.S. STOCKS ON THE MOVE-Axovant, OncoMed, Sito Mobile ... - Nasdaq
www.nasdaq.com - April 11 at 6:04 AM
finance.yahoo.com logoMedivation Founder Takes Helm at Axovant, Shares Spike
finance.yahoo.com - April 10 at 3:45 PM
finance.yahoo.com logoMedivation Founder Takes Helm at Axovant, Shares Spike
finance.yahoo.com - April 10 at 3:45 PM
finance.yahoo.com logoA company developing a drug to treat Alzheimer's disease just got a new CEO — and the stock is jumping
finance.yahoo.com - April 10 at 3:45 PM
finance.yahoo.com logoA company developing a drug to treat Alzheimer's disease just got a new CEO — and the stock is jumping
finance.yahoo.com - April 10 at 3:45 PM
finance.yahoo.com logoAxovant stock surges 28% on new CEO
finance.yahoo.com - April 10 at 3:45 PM
finance.yahoo.com logoAxovant stock surges 28% on new CEO
finance.yahoo.com - April 10 at 3:45 PM
finance.yahoo.com logo[$$] The $400 Million Man
finance.yahoo.com - April 10 at 3:45 PM
finance.yahoo.com logo[$$] The $400 Million Man
finance.yahoo.com - April 10 at 3:45 PM
finance.yahoo.com logo[$$] Axovant shares jump after Medivation founder named chief
finance.yahoo.com - April 10 at 3:45 PM
finance.yahoo.com logo[$$] Axovant shares jump after Medivation founder named chief
finance.yahoo.com - April 10 at 3:45 PM
finance.yahoo.com logoBiotechs Split: Axovant Rides CEO Swap, But Celgene Partner Dives
finance.yahoo.com - April 10 at 3:45 PM
finance.yahoo.com logoBiotechs Split: Axovant Rides CEO Swap, But Celgene Partner Dives
finance.yahoo.com - April 10 at 3:45 PM
nasdaq.com logoAxovant Sciences Ltd. (AXON) Has Surged To A New High After New CEO Named
www.nasdaq.com - April 10 at 10:07 AM
finance.yahoo.com logoAxovant Sciences Announces Appointment of Dr. David Hung as Chief Executive Officer and Expansion of Board of Directors
finance.yahoo.com - April 10 at 10:07 AM
americanbankingnews.com logo Analysts Expect Axovant Sciences Ltd (AXON) Will Announce Quarterly Sales of $0.00
www.americanbankingnews.com - April 8 at 8:44 AM
americanbankingnews.com logoAxovant Sciences Ltd (AXON) Expected to Announce Earnings of -$0.51 Per Share
www.americanbankingnews.com - April 6 at 8:22 PM
americanbankingnews.com logoAxovant Sciences Ltd (AXON) Given Consensus Recommendation of "Buy" by Analysts
www.americanbankingnews.com - March 28 at 12:40 PM
americanbankingnews.com logoAxovant Sciences' (AXON) Buy Rating Reaffirmed at Oppenheimer Holdings Inc.
www.americanbankingnews.com - March 28 at 7:10 AM
americanbankingnews.com logoAxovant Sciences' (AXON) "Buy" Rating Reaffirmed at Oppenheimer Holdings Inc.
www.americanbankingnews.com - March 25 at 12:58 AM
finance.yahoo.com logoAxovant Sciences to Present at Upcoming Scientific Meetings
finance.yahoo.com - March 21 at 9:07 PM
finance.yahoo.com logoAxovant Sciences Announces Presentation Time Change at Oppenheimer Healthcare Conference
finance.yahoo.com - March 21 at 12:26 PM

Social

Chart

Axovant Sciences Ltd (AXON) Chart for Sunday, May, 28, 2017

This page was last updated on 5/28/2017 by MarketBeat.com Staff